Aficamten Dose Titration for Obstructive HCM Gradient Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hypertrophic cardiomyopathy leads to heart muscle thickening, reducing the heart's ability to relax and fill with blood, causing symptoms like chest pain, dizziness, and increasing the risk of arrhythmias and heart failure, with existing therapies inadequate in addressing adverse cardiac remodeling and high ventricular outflow tract pressure gradients.
Innovation Solution
Administration of a cardiac myosin inhibitor (CK-3773274 or aficamten) to reduce left ventricular outflow tract pressure gradients to less than 30 mmHg and post-Valsalva gradients to less than 50 mmHg, with dose titration based on echocardiogram results to optimize treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for hypertrophic cardiomyopathy, then some symptomatic relief may be achieved, but adverse cardiac remodeling and high ventricular outflow tract pressure gradients remain inadequately addressed
Solution Approach 1:
The patent employs parameter changes by modifying the therapeutic approach through selective beta-blockade therapy that specifically targets ventricular outflow tract pressure gradient reduction. The treatment changes physiological parameters including heart rate, contractility, and vascular resistance to achieve gradient reduction below 30 mmHg, thereby addressing the harmful effect while improving reliability of treatment outcomes for adverse cardiac remodeling
Solution Approach 2:
The patent implements feedback mechanisms through continuous echocardiographic monitoring of ventricular outflow tract pressure gradients and cardiac function parameters. This feedback loop allows dynamic adjustment of therapy intensity and duration, enabling the treatment to respond to patient-specific responses and optimize the reduction of pressure gradients while addressing adverse cardiac remodeling effectively
2Productivity
If intensive therapy is applied to reduce pressure gradients quickly, then symptomatic relief is achieved faster, but risk of overtreatment and adverse effects increases
Solution Approach 1:
The patent applies dynamics by implementing a flexible, adaptive treatment protocol that adjusts therapy intensity based on real-time patient response. The selective beta-blockade therapy is modulated dynamically through dose adjustments and duration modifications guided by echocardiographic parameters, allowing rapid pressure gradient reduction when appropriate while preventing overtreatment through continuous monitoring and adaptive control
Solution Approach 2:
The patent employs self-service principles through patient-specific therapy customization where treatment parameters are tailored to individual patient characteristics and response patterns. The therapy adapts to each patient's unique physiological profile, enabling effective pressure gradient reduction at the optimal pace for each individual while minimizing adverse effects through personalized dosing and monitoring protocols
Data Source
AI summary
Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.